Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Providing Nursing Insight Into the Management of irAEs in Lung Cancer

May 4th 2021

Marianne Davies, NP, DNP, MSN, BSN, discussed the potential severity of immune-related adverse effects and detailed recommended management strategies for patients receiving checkpoint inhibitors, especially in lung cancer.

Molecular Testing Results Are Critical Amid an Expanding Targeted Therapy Paradigm in Advanced NSCLC

May 3rd 2021

Julia K. Rotow, MD, discusses how she approaches molecularly testing in patients with liquid- and tissue-based biopsies, the importance of waiting to initiate immunotherapy until a patient’s molecular testing results are confirmed, and other nuances that she considers when treating patients with advanced non–small cell lung cancer.

Research Efforts Mount With Immunotherapy in Advanced NSCLC

May 3rd 2021

Christopher G. Azzoli, MD, discusses the importance of identifying molecular aberrations prior to starting a patient with advanced non–small cell lung cancer on immunotherapy, ongoing research aimed at furthering the immunotherapy paradigm, and explained why novel biomarkers of response to immunotherapy are needed.

Trilaciclib Tackles Myelosuppression in SCLC

May 1st 2021

Lowell L. Hart, MD, discusses trilaciclib’s unique role in patients with ES-SCLC who experience myelosuppression, as well as the future role of the agent.

Dr. Pacheco on the Mechanism of Action of Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic NSCLC

April 30th 2021

Jose Pacheco, MD, discusses the mechanism of action of trastuzumab deruxtecan in patients with HER2-overexpressing metastatic non–small cell lung cancer.

Dr. Liu on Common NRG1 Fusion Partners in NSCLC

April 29th 2021

Stephen Liu, MD, discusses common NRG1 fusion partners in patients with non–small cell lung cancer.

Dr. Velcheti on the Importance of Real-World Data in NSCLC

April 28th 2021

Vamsidhar Velcheti, MD, discusses the importance of real-world data for patients with non–small cell lung cancer.

FDA Grants Priority Review to Mobocertinib for Advanced EGFR Exon 20–Mutant NSCLC

April 28th 2021

The FDA has granted a priority review designation to a new drug application for mobocertinib for the treatment of adult patients with EGFR exon 20 insertion mutation–positive metastatic non–small cell lung cancer, as detected via an FDA-approved assay, who have received previous platinum-based chemotherapy.

Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLC

April 27th 2021

Roy H. Decker, MD, PhD, discusses the use of pembrolizumab with concurrent chemoradiotherapy in patients with inoperable, locally advanced non–small cell lung cancer.

Trilaciclib Added to NCCN Guidelines for SCLC and Hematopoietic Growth Factors

April 27th 2021

The National Comprehensive Cancer Network® has added the CDK4/6 inhibitor trilaciclib to its Clinical Practice Guidelines in Oncology for small cell lung cancer as well as for supportive care for hematopoietic growth factors.

Dr. Mohindra on the Impact of Lurbinectedin in SCLC

April 27th 2021

Nisha A. Mohindra, MD, discusses the impact of the FDA approval of lurbinectedin in the treatment of patients with small cell lung cancer.

EU Panel Recommends Adjuvant Osimertinib in Early-Stage EGFR+ NSCLC

April 26th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended osimertinib for the adjuvant treatment of adult patients with stage IB, II, or IIIA EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.

EU Panel Recommends Nivolumab/Ipilimumab in Frontline Unresectable Malignant Pleural Mesothelioma

April 23rd 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the combination of nivolumab and ipilimumab as a frontline treatment for adult patients with unresectable malignant pleural mesothelioma.

A New Therapeutic Target in Non–Small Cell Lung Cancer: HER2

April 23rd 2021

This article summarizes key data presented during a virtual OncLive® Scientific Interchange & Workshop in which oncologists who specialize in lung cancer treatment discussed their practices for HER2 testing and the potential role of emerging antibody-drug conjugates and novel HER2-targeted small-molecule tyrosine kinase inhibitors for treatment of HER2-altered NSCLC.

MET Inhibitors in NSCLC: Toxicity Management

April 19th 2021

Drs Joshua M. Bauml and Benjamin Levy highlight more common adverse events associated with MET inhibitors used to treat MET exon 14 skipping mutations in non–small cell lung cancer and share strategies to help manage patients on therapy.

MET Inhibitors in NSCLC: Treatment Selection

April 19th 2021

A comparison between the MET inhibitors available to treat MET exon 14 skipping mutations in non–small cell lung cancer and factors that should be considered when selecting a type 1 or type 2 MET-directed therapy.

Osimertinib Combos Are Under Evaluation in EGFR+ NSCLC

April 19th 2021

Jyoti D. Patel, MD, discusses the evolving use of osimertinib in EGFR-mutant NSCLC and emerging targeted agents for patients with EGFR exon 20 insertion mutations.

Role of PORT Diminishes in Early-Stage NSCLC, as Novel Approaches Emerge for Unresectable Stage III Disease

April 17th 2021

Kristen Marrone, MD, discusses the evolving role of postoperative radiotherapy in early-stage non–small cell lung cancer and ongoing trials examining the use of immunotherapy and targeted agents in patients with unresectable stage III disease.

Dr. Haigentz on the Importance of Adjuvant Osimertinib in EGFR+ NSCLC

April 16th 2021

Missak Haigentz Jr., MD, discusses the importance of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Accelerating Advances in NSCLC Underscore the Importance of Accessibility

April 16th 2021

Jacob Sands, MD, discussed current approaches to the treatment of patients with early-stage and locally advanced non–small cell lung cancer.